The Arrowg+ard Blue Advance PICC is designed to protect both internal and external catheter surfaces with chlorhexidine, reducing the risk of these catheter-related complications:
Demonstrated a 92% reduction of fibrin sheath accumulation on catheter surfaces at 31 days2
99.99% colonization reduction in gram-positive and gram-negative bacterial and fungal pathogens for at least 30 days1
Reduced thrombotic intraluminal occlusion as evidenced by 51% reduction in flush pressure to clear thrombus3
Arrowg+ard Blue Advance PICC vs. Unprotected PICCs
In an intravascular in vivo model, Arrowg+ard Blue Advance Protection demonstrated a total of 92% reduction in fibrin sheath when challenged with Staph aureus, as compared to an uncoated PICC control. The Arrowg+ard Blue Advance PICC survived until the end of the study (mean 31 days) with no clinical signs of infection.2
Unprotected PICC Control Catheter
Day 5: Highly infected tissue and significant thrombus formation.
Arrowg+ard Blue Advance PICC
Day 31: Minimal thrombus formation and absence of microbial colonization.*
Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance PICC is contraindicated in the following areas:
• Patients with known hypersensitivity to chlorhexidine
• In presence of device related infections
• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway.
No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Blue FlexTip, SecondSite, TaperFree, VPS G4, and VPS Rhythm are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners. MCI-2020-0426